Immunoassay kit for detecting M-type phospholipase A2 receptor-IgG as well as preparation method and detection method of immunoassay kit

Abstract

The invention discloses an immunoassay kit for detecting M-type phospholipase A2 receptor-IgG as well as a preparation method and detection method of the immunoassay kit, and belongs to the field of immunoassay technologies and nano biotechnologies. The kit comprises a reaction buffer, a cleaning solution, an enhancement solution, a PLA2R-coated magnetic particle solution, an europium-labeled goatanti-human IgG antibody solution which are integrated on a reagent strip and is additionally provided with two bottles of freeze-dried calibrators of anti-PLA2R-IgG. The kit can provide a reaction system close to a homogeneous phase, the content of anti-PLA2R-IgG is detected, the detection time is shortened, the efficiency is improved, and convenience is provided for clinical use.

Description

technical field [0001] The invention belongs to the field of immune detection and analysis technology and nano-biotechnology, and specifically relates to a time-resolved fluorescent immunoassay kit based on M-type phospholipase A2 receptor (PLA2R)-IgG, and a preparation method and a detection method thereof. Background technique [0002] The prevalence of kidney disease among Chinese adults reaches 10.8%. The pathological changes of the kidneys are mainly the increase of the permeability of the glomerular basement membrane. Elevated blood lipids and high edema. Among them, membranous nephropathy (MN) is one of the most common causes of adult nephrotic syndrome. (second membranous nephropathy, SMN). IMN accounts for about two-thirds of membranous nephropathy; SMN accounts for about one-third of membranous nephropathy. Common pathogenic factors include autoimmune diseases, viral infections, tumors, and drugs; [0003] At present, the diagnosis of membranous nephropathy depe...

AI Technical Summary

Problems solved by technology

Hofstra et al. found that in IMN patients whose expression of anti-PLA2R antibody turned negative or whose titer decreased, the remission rate or partial remission rate of proteinuria reached 88%, while in patients whose anti-PLA2R antibody did not turn negative or whose titer did not decrease, The remission rate or partial remission rate of proteinuria is only 33%, and for patients with continuous high-level expression of anti-PLA2R antibody concentration before and after treatment, the disease is not easy to be remitted or is more likely to relapse after remission

Images